Form 4: Insider Plans Future Stake Increase in ENDRA Life Sciences

Anthony DiGiandomenico, a Director at ENDRA Life Sciences Inc., plans to acquire 70,822 shares of common stock and 141,644 warrants in a private placement on October 10, 2025.

Summary

• Anthony DiGiandomenico, a Director of ENDRA Life Sciences Inc. (NDRA), will acquire securities in a private placement.
• The transaction, scheduled for October 10, 2025, involves the purchase of 70,822 shares of Common Stock at a price of $7.06 per share.
• Concurrently, 141,644 Warrants will be acquired, with each warrant exercisable for two shares of Common Stock.
• The Warrants have an exercise price of $6.81 per share and will be exercisable from October 15, 2025, expiring on October 15, 2030.
• Following these transactions, DiGiandomenico's beneficial ownership will include 76,265 shares of Common Stock (including unvested restricted stock units) and 141,644 Warrants.

Sentiment

Score: 8

Explanation: The planned significant insider purchase of both common stock and warrants indicates strong confidence from a director, which is generally viewed very positively by the market.

Positives

• A Director's planned acquisition of a significant number of shares and warrants in a private placement signals strong insider confidence in the company's future prospects.
• The private placement structure indicates a direct investment by management, aligning their interests with those of other shareholders.

Future Outlook

The planned acquisition by a director suggests a positive internal outlook on the company's future performance and valuation.

Industry Context

This insider transaction reflects a director's individual investment decision and does not directly provide broader industry trend insights. However, it could be interpreted as a belief in ENDRA Life Sciences' competitive position or future growth within its specific market segment.

Related Party Transactions

• The transaction involves the acquisition of securities by a director from the Issuer in a private placement, which is a related party transaction.

Stakeholder Impact

• Shareholders may view this insider buying as a positive signal, potentially increasing confidence in the company's stock.
• The company benefits from the capital raised through the private placement.

Key Dates

Recommendation

The planned insider acquisition by a director is a strong positive signal, indicating confidence in the company's future. While this single Form 4 does not provide a comprehensive basis for a 'buy' recommendation without broader financial analysis, it suggests a favorable outlook and warrants holding existing positions or considering further due diligence for potential investment.

Keywords

ENDRA Life Sciences, NDRA, Form 4, Insider Transaction, Private Placement, Stock Acquisition, Warrants, Anthony DiGiandomenico, Director